

Global Ustekinumab Market Growth 2023-2029

<https://marketpublishers.com/r/G6EF5BA11CC3EN.html>

Date: March 2023

Pages: 101

Price: US\$ 3,660.00 (Single User License)

ID: G6EF5BA11CC3EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses.

LPI (LP Information)' newest research report, the "Ustekinumab Industry Forecast" looks at past sales and reviews total world Ustekinumab sales in 2022, providing a comprehensive analysis by region and market sector of projected Ustekinumab sales for 2023 through 2029. With Ustekinumab sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Ustekinumab industry.

This Insight Report provides a comprehensive analysis of the global Ustekinumab landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ustekinumab portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Ustekinumab market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ustekinumab and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ustekinumab.

The global Ustekinumab market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Ustekinumab is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Ustekinumab is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Ustekinumab is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Ustekinumab players cover Meiji, Johnson & Johnson, Alvotech, Fuji Pharma, Mitsubishi Tanabe, Stada, EPIRUS BioPharma, Formycon and NeuClone, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Ustekinumab market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Intravenous

Subcutaneous

Segmentation by application

Arthritis

Colitis

Lupus Erythematosus

Myositis Multiplex With Palmoplantar Pustulosis

Cirrhosis Of The Liver

Sarcoidosis

Diabetes

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Meiji

Johnson & Johnson

Alvotech

Fuji Pharma

Mitsubishi Tanabe

Stada

EPIRUS BioPharma

Formycon

NeuClone

Outlook Therapeutics

Harvest Moon Pharma

BioXpress

Key Questions Addressed in this Report

What is the 10-year outlook for the global Ustekinumab market?

What factors are driving Ustekinumab market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Ustekinumab market opportunities vary by end market size?

How does Ustekinumab break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Ustekinumab Annual Sales 2018-2029
 - 2.1.2 World Current & Future Analysis for Ustekinumab by Geographic Region, 2018, 2022 & 2029
 - 2.1.3 World Current & Future Analysis for Ustekinumab by Country/Region, 2018, 2022 & 2029
- 2.2 Ustekinumab Segment by Type
 - 2.2.1 Intravenous
 - 2.2.2 Subcutaneous
- 2.3 Ustekinumab Sales by Type
 - 2.3.1 Global Ustekinumab Sales Market Share by Type (2018-2023)
 - 2.3.2 Global Ustekinumab Revenue and Market Share by Type (2018-2023)
 - 2.3.3 Global Ustekinumab Sale Price by Type (2018-2023)
- 2.4 Ustekinumab Segment by Application
 - 2.4.1 Arthritis
 - 2.4.2 Colitis
 - 2.4.3 Lupus Erythematosus
 - 2.4.4 Myositis Multiplex With Palmoplantar Pustulosis
 - 2.4.5 Cirrhosis Of The Liver
 - 2.4.6 Sarcoidosis
 - 2.4.7 Diabetes
 - 2.4.8 Other
- 2.5 Ustekinumab Sales by Application
 - 2.5.1 Global Ustekinumab Sale Market Share by Application (2018-2023)

2.5.2 Global Ustekinumab Revenue and Market Share by Application (2018-2023)

2.5.3 Global Ustekinumab Sale Price by Application (2018-2023)

3 GLOBAL USTEKINUMAB BY COMPANY

3.1 Global Ustekinumab Breakdown Data by Company

3.1.1 Global Ustekinumab Annual Sales by Company (2018-2023)

3.1.2 Global Ustekinumab Sales Market Share by Company (2018-2023)

3.2 Global Ustekinumab Annual Revenue by Company (2018-2023)

3.2.1 Global Ustekinumab Revenue by Company (2018-2023)

3.2.2 Global Ustekinumab Revenue Market Share by Company (2018-2023)

3.3 Global Ustekinumab Sale Price by Company

3.4 Key Manufacturers Ustekinumab Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Ustekinumab Product Location Distribution

3.4.2 Players Ustekinumab Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR USTEKINUMAB BY GEOGRAPHIC REGION

4.1 World Historic Ustekinumab Market Size by Geographic Region (2018-2023)

4.1.1 Global Ustekinumab Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Ustekinumab Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Ustekinumab Market Size by Country/Region (2018-2023)

4.2.1 Global Ustekinumab Annual Sales by Country/Region (2018-2023)

4.2.2 Global Ustekinumab Annual Revenue by Country/Region (2018-2023)

4.3 Americas Ustekinumab Sales Growth

4.4 APAC Ustekinumab Sales Growth

4.5 Europe Ustekinumab Sales Growth

4.6 Middle East & Africa Ustekinumab Sales Growth

5 AMERICAS

5.1 Americas Ustekinumab Sales by Country

5.1.1 Americas Ustekinumab Sales by Country (2018-2023)

- 5.1.2 Americas Ustekinumab Revenue by Country (2018-2023)
- 5.2 Americas Ustekinumab Sales by Type
- 5.3 Americas Ustekinumab Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Ustekinumab Sales by Region
 - 6.1.1 APAC Ustekinumab Sales by Region (2018-2023)
 - 6.1.2 APAC Ustekinumab Revenue by Region (2018-2023)
- 6.2 APAC Ustekinumab Sales by Type
- 6.3 APAC Ustekinumab Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Ustekinumab by Country
 - 7.1.1 Europe Ustekinumab Sales by Country (2018-2023)
 - 7.1.2 Europe Ustekinumab Revenue by Country (2018-2023)
- 7.2 Europe Ustekinumab Sales by Type
- 7.3 Europe Ustekinumab Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Ustekinumab by Country

- 8.1.1 Middle East & Africa Ustekinumab Sales by Country (2018-2023)
- 8.1.2 Middle East & Africa Ustekinumab Revenue by Country (2018-2023)
- 8.2 Middle East & Africa Ustekinumab Sales by Type
- 8.3 Middle East & Africa Ustekinumab Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Ustekinumab
- 10.3 Manufacturing Process Analysis of Ustekinumab
- 10.4 Industry Chain Structure of Ustekinumab

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
 - 11.1.1 Direct Channels
 - 11.1.2 Indirect Channels
- 11.2 Ustekinumab Distributors
- 11.3 Ustekinumab Customer

12 WORLD FORECAST REVIEW FOR USTEKINUMAB BY GEOGRAPHIC REGION

- 12.1 Global Ustekinumab Market Size Forecast by Region
 - 12.1.1 Global Ustekinumab Forecast by Region (2024-2029)
 - 12.1.2 Global Ustekinumab Annual Revenue Forecast by Region (2024-2029)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country

- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Ustekinumab Forecast by Type
- 12.7 Global Ustekinumab Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Meiji

- 13.1.1 Meiji Company Information
- 13.1.2 Meiji Ustekinumab Product Portfolios and Specifications
- 13.1.3 Meiji Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.1.4 Meiji Main Business Overview
- 13.1.5 Meiji Latest Developments

13.2 Johnson & Johnson

- 13.2.1 Johnson & Johnson Company Information
- 13.2.2 Johnson & Johnson Ustekinumab Product Portfolios and Specifications
- 13.2.3 Johnson & Johnson Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.2.4 Johnson & Johnson Main Business Overview
- 13.2.5 Johnson & Johnson Latest Developments

13.3 Alvotech

- 13.3.1 Alvotech Company Information
- 13.3.2 Alvotech Ustekinumab Product Portfolios and Specifications
- 13.3.3 Alvotech Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.3.4 Alvotech Main Business Overview
- 13.3.5 Alvotech Latest Developments

13.4 Fuji Pharma

- 13.4.1 Fuji Pharma Company Information
- 13.4.2 Fuji Pharma Ustekinumab Product Portfolios and Specifications
- 13.4.3 Fuji Pharma Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.4.4 Fuji Pharma Main Business Overview
- 13.4.5 Fuji Pharma Latest Developments

13.5 Mitsubishi Tanabe

- 13.5.1 Mitsubishi Tanabe Company Information
- 13.5.2 Mitsubishi Tanabe Ustekinumab Product Portfolios and Specifications
- 13.5.3 Mitsubishi Tanabe Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.5.4 Mitsubishi Tanabe Main Business Overview
- 13.5.5 Mitsubishi Tanabe Latest Developments

13.6 Stada

13.6.1 Stada Company Information

13.6.2 Stada Ustekinumab Product Portfolios and Specifications

13.6.3 Stada Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)

13.6.4 Stada Main Business Overview

13.6.5 Stada Latest Developments

13.7 EPIRUS BioPharma

13.7.1 EPIRUS BioPharma Company Information

13.7.2 EPIRUS BioPharma Ustekinumab Product Portfolios and Specifications

13.7.3 EPIRUS BioPharma Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)

13.7.4 EPIRUS BioPharma Main Business Overview

13.7.5 EPIRUS BioPharma Latest Developments

13.8 Formycon

13.8.1 Formycon Company Information

13.8.2 Formycon Ustekinumab Product Portfolios and Specifications

13.8.3 Formycon Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)

13.8.4 Formycon Main Business Overview

13.8.5 Formycon Latest Developments

13.9 NeuClone

13.9.1 NeuClone Company Information

13.9.2 NeuClone Ustekinumab Product Portfolios and Specifications

13.9.3 NeuClone Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)

13.9.4 NeuClone Main Business Overview

13.9.5 NeuClone Latest Developments

13.10 Outlook Therapeutics

13.10.1 Outlook Therapeutics Company Information

13.10.2 Outlook Therapeutics Ustekinumab Product Portfolios and Specifications

13.10.3 Outlook Therapeutics Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)

13.10.4 Outlook Therapeutics Main Business Overview

13.10.5 Outlook Therapeutics Latest Developments

13.11 Harvest Moon Pharma

13.11.1 Harvest Moon Pharma Company Information

13.11.2 Harvest Moon Pharma Ustekinumab Product Portfolios and Specifications

13.11.3 Harvest Moon Pharma Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)

13.11.4 Harvest Moon Pharma Main Business Overview

13.11.5 Harvest Moon Pharma Latest Developments

13.12 BioXpress

13.12.1 BioXpress Company Information

13.12.2 BioXpress Ustekinumab Product Portfolios and Specifications

13.12.3 BioXpress Ustekinumab Sales, Revenue, Price and Gross Margin (2018-2023)

13.12.4 BioXpress Main Business Overview

13.12.5 BioXpress Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Ustekinumab Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)
- Table 2. Ustekinumab Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)
- Table 3. Major Players of Intravenous
- Table 4. Major Players of Subcutaneous
- Table 5. Global Ustekinumab Sales by Type (2018-2023) & (K Units)
- Table 6. Global Ustekinumab Sales Market Share by Type (2018-2023)
- Table 7. Global Ustekinumab Revenue by Type (2018-2023) & (\$ million)
- Table 8. Global Ustekinumab Revenue Market Share by Type (2018-2023)
- Table 9. Global Ustekinumab Sale Price by Type (2018-2023) & (US\$/Unit)
- Table 10. Global Ustekinumab Sales by Application (2018-2023) & (K Units)
- Table 11. Global Ustekinumab Sales Market Share by Application (2018-2023)
- Table 12. Global Ustekinumab Revenue by Application (2018-2023)
- Table 13. Global Ustekinumab Revenue Market Share by Application (2018-2023)
- Table 14. Global Ustekinumab Sale Price by Application (2018-2023) & (US\$/Unit)
- Table 15. Global Ustekinumab Sales by Company (2018-2023) & (K Units)
- Table 16. Global Ustekinumab Sales Market Share by Company (2018-2023)
- Table 17. Global Ustekinumab Revenue by Company (2018-2023) (\$ Millions)
- Table 18. Global Ustekinumab Revenue Market Share by Company (2018-2023)
- Table 19. Global Ustekinumab Sale Price by Company (2018-2023) & (US\$/Unit)
- Table 20. Key Manufacturers Ustekinumab Producing Area Distribution and Sales Area
- Table 21. Players Ustekinumab Products Offered
- Table 22. Ustekinumab Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
- Table 23. New Products and Potential Entrants
- Table 24. Mergers & Acquisitions, Expansion
- Table 25. Global Ustekinumab Sales by Geographic Region (2018-2023) & (K Units)
- Table 26. Global Ustekinumab Sales Market Share Geographic Region (2018-2023)
- Table 27. Global Ustekinumab Revenue by Geographic Region (2018-2023) & (\$ millions)
- Table 28. Global Ustekinumab Revenue Market Share by Geographic Region (2018-2023)
- Table 29. Global Ustekinumab Sales by Country/Region (2018-2023) & (K Units)
- Table 30. Global Ustekinumab Sales Market Share by Country/Region (2018-2023)
- Table 31. Global Ustekinumab Revenue by Country/Region (2018-2023) & (\$ millions)

Table 32. Global Ustekinumab Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Ustekinumab Sales by Country (2018-2023) & (K Units)
Table 34. Americas Ustekinumab Sales Market Share by Country (2018-2023)
Table 35. Americas Ustekinumab Revenue by Country (2018-2023) & (\$ Millions)
Table 36. Americas Ustekinumab Revenue Market Share by Country (2018-2023)
Table 37. Americas Ustekinumab Sales by Type (2018-2023) & (K Units)
Table 38. Americas Ustekinumab Sales by Application (2018-2023) & (K Units)
Table 39. APAC Ustekinumab Sales by Region (2018-2023) & (K Units)
Table 40. APAC Ustekinumab Sales Market Share by Region (2018-2023)
Table 41. APAC Ustekinumab Revenue by Region (2018-2023) & (\$ Millions)
Table 42. APAC Ustekinumab Revenue Market Share by Region (2018-2023)
Table 43. APAC Ustekinumab Sales by Type (2018-2023) & (K Units)
Table 44. APAC Ustekinumab Sales by Application (2018-2023) & (K Units)
Table 45. Europe Ustekinumab Sales by Country (2018-2023) & (K Units)
Table 46. Europe Ustekinumab Sales Market Share by Country (2018-2023)
Table 47. Europe Ustekinumab Revenue by Country (2018-2023) & (\$ Millions)
Table 48. Europe Ustekinumab Revenue Market Share by Country (2018-2023)
Table 49. Europe Ustekinumab Sales by Type (2018-2023) & (K Units)
Table 50. Europe Ustekinumab Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Ustekinumab Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Ustekinumab Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Ustekinumab Revenue by Country (2018-2023) & (\$ Millions)
Table 54. Middle East & Africa Ustekinumab Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Ustekinumab Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Ustekinumab Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Ustekinumab
Table 58. Key Market Challenges & Risks of Ustekinumab
Table 59. Key Industry Trends of Ustekinumab
Table 60. Ustekinumab Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Ustekinumab Distributors List
Table 63. Ustekinumab Customer List
Table 64. Global Ustekinumab Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Ustekinumab Revenue Forecast by Region (2024-2029) & (\$ millions)
Table 66. Americas Ustekinumab Sales Forecast by Country (2024-2029) & (K Units)

Table 67. Americas Ustekinumab Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 68. APAC Ustekinumab Sales Forecast by Region (2024-2029) & (K Units)

Table 69. APAC Ustekinumab Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 70. Europe Ustekinumab Sales Forecast by Country (2024-2029) & (K Units)

Table 71. Europe Ustekinumab Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 72. Middle East & Africa Ustekinumab Sales Forecast by Country (2024-2029) & (K Units)

Table 73. Middle East & Africa Ustekinumab Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 74. Global Ustekinumab Sales Forecast by Type (2024-2029) & (K Units)

Table 75. Global Ustekinumab Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 76. Global Ustekinumab Sales Forecast by Application (2024-2029) & (K Units)

Table 77. Global Ustekinumab Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 78. Meiji Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors

Table 79. Meiji Ustekinumab Product Portfolios and Specifications

Table 80. Meiji Ustekinumab Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 81. Meiji Main Business

Table 82. Meiji Latest Developments

Table 83. Johnson & Johnson Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors

Table 84. Johnson & Johnson Ustekinumab Product Portfolios and Specifications

Table 85. Johnson & Johnson Ustekinumab Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 86. Johnson & Johnson Main Business

Table 87. Johnson & Johnson Latest Developments

Table 88. Alvotech Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors

Table 89. Alvotech Ustekinumab Product Portfolios and Specifications

Table 90. Alvotech Ustekinumab Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 91. Alvotech Main Business

Table 92. Alvotech Latest Developments

Table 93. Fuji Pharma Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors

Table 94. Fuji Pharma Ustekinumab Product Portfolios and Specifications

Table 95. Fuji Pharma Ustekinumab Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 96. Fuji Pharma Main Business

Table 97. Fuji Pharma Latest Developments

Table 98. Mitsubishi Tanabe Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors

Table 99. Mitsubishi Tanabe Ustekinumab Product Portfolios and Specifications

Table 100. Mitsubishi Tanabe Ustekinumab Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 101. Mitsubishi Tanabe Main Business

Table 102. Mitsubishi Tanabe Latest Developments

Table 103. Stada Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors

Table 104. Stada Ustekinumab Product Portfolios and Specifications

Table 105. Stada Ustekinumab Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 106. Stada Main Business

Table 107. Stada Latest Developments

Table 108. EPIRUS BioPharma Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors

Table 109. EPIRUS BioPharma Ustekinumab Product Portfolios and Specifications

Table 110. EPIRUS BioPharma Ustekinumab Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 111. EPIRUS BioPharma Main Business

Table 112. EPIRUS BioPharma Latest Developments

Table 113. Formycon Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors

Table 114. Formycon Ustekinumab Product Portfolios and Specifications

Table 115. Formycon Ustekinumab Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 116. Formycon Main Business

Table 117. Formycon Latest Developments

Table 118. NeuClone Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors

Table 119. NeuClone Ustekinumab Product Portfolios and Specifications

Table 120. NeuClone Ustekinumab Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 121. NeuClone Main Business

Table 122. NeuClone Latest Developments

Table 123. Outlook Therapeutics Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors

Table 124. Outlook Therapeutics Ustekinumab Product Portfolios and Specifications

Table 125. Outlook Therapeutics Ustekinumab Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 126. Outlook Therapeutics Main Business

Table 127. Outlook Therapeutics Latest Developments

Table 128. Harvest Moon Pharma Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors

Table 129. Harvest Moon Pharma Ustekinumab Product Portfolios and Specifications

Table 130. Harvest Moon Pharma Ustekinumab Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 131. Harvest Moon Pharma Main Business

Table 132. Harvest Moon Pharma Latest Developments

Table 133. BioXpress Basic Information, Ustekinumab Manufacturing Base, Sales Area and Its Competitors

Table 134. BioXpress Ustekinumab Product Portfolios and Specifications

Table 135. BioXpress Ustekinumab Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 136. BioXpress Main Business

Table 137. BioXpress Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Ustekinumab
- Figure 2. Ustekinumab Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Ustekinumab Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Ustekinumab Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Ustekinumab Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Intravenous
- Figure 10. Product Picture of Subcutaneous
- Figure 11. Global Ustekinumab Sales Market Share by Type in 2022
- Figure 12. Global Ustekinumab Revenue Market Share by Type (2018-2023)
- Figure 13. Ustekinumab Consumed in Arthritis
- Figure 14. Global Ustekinumab Market: Arthritis (2018-2023) & (K Units)
- Figure 15. Ustekinumab Consumed in Colitis
- Figure 16. Global Ustekinumab Market: Colitis (2018-2023) & (K Units)
- Figure 17. Ustekinumab Consumed in Lupus Erythematosus
- Figure 18. Global Ustekinumab Market: Lupus Erythematosus (2018-2023) & (K Units)
- Figure 19. Ustekinumab Consumed in Myositis Multiplex With Palmoplantar Pustulosis
- Figure 20. Global Ustekinumab Market: Myositis Multiplex With Palmoplantar Pustulosis (2018-2023) & (K Units)
- Figure 21. Ustekinumab Consumed in Cirrhosis Of The Liver
- Figure 22. Global Ustekinumab Market: Cirrhosis Of The Liver (2018-2023) & (K Units)
- Figure 23. Ustekinumab Consumed in Sarcoidosis
- Figure 24. Global Ustekinumab Market: Sarcoidosis (2018-2023) & (K Units)
- Figure 25. Ustekinumab Consumed in Diabetes
- Figure 26. Global Ustekinumab Market: Diabetes (2018-2023) & (K Units)
- Figure 27. Ustekinumab Consumed in Other
- Figure 28. Global Ustekinumab Market: Other (2018-2023) & (K Units)
- Figure 29. Global Ustekinumab Sales Market Share by Application (2022)
- Figure 30. Global Ustekinumab Revenue Market Share by Application in 2022
- Figure 31. Ustekinumab Sales Market by Company in 2022 (K Units)
- Figure 32. Global Ustekinumab Sales Market Share by Company in 2022
- Figure 33. Ustekinumab Revenue Market by Company in 2022 (\$ Million)
- Figure 34. Global Ustekinumab Revenue Market Share by Company in 2022

- Figure 35. Global Ustekinumab Sales Market Share by Geographic Region (2018-2023)
- Figure 36. Global Ustekinumab Revenue Market Share by Geographic Region in 2022
- Figure 37. Americas Ustekinumab Sales 2018-2023 (K Units)
- Figure 38. Americas Ustekinumab Revenue 2018-2023 (\$ Millions)
- Figure 39. APAC Ustekinumab Sales 2018-2023 (K Units)
- Figure 40. APAC Ustekinumab Revenue 2018-2023 (\$ Millions)
- Figure 41. Europe Ustekinumab Sales 2018-2023 (K Units)
- Figure 42. Europe Ustekinumab Revenue 2018-2023 (\$ Millions)
- Figure 43. Middle East & Africa Ustekinumab Sales 2018-2023 (K Units)
- Figure 44. Middle East & Africa Ustekinumab Revenue 2018-2023 (\$ Millions)
- Figure 45. Americas Ustekinumab Sales Market Share by Country in 2022
- Figure 46. Americas Ustekinumab Revenue Market Share by Country in 2022
- Figure 47. Americas Ustekinumab Sales Market Share by Type (2018-2023)
- Figure 48. Americas Ustekinumab Sales Market Share by Application (2018-2023)
- Figure 49. United States Ustekinumab Revenue Growth 2018-2023 (\$ Millions)
- Figure 50. Canada Ustekinumab Revenue Growth 2018-2023 (\$ Millions)
- Figure 51. Mexico Ustekinumab Revenue Growth 2018-2023 (\$ Millions)
- Figure 52. Brazil Ustekinumab Revenue Growth 2018-2023 (\$ Millions)
- Figure 53. APAC Ustekinumab Sales Market Share by Region in 2022
- Figure 54. APAC Ustekinumab Revenue Market Share by Regions in 2022
- Figure 55. APAC Ustekinumab Sales Market Share by Type (2018-2023)
- Figure 56. APAC Ustekinumab Sales Market Share by Application (2018-2023)
- Figure 57. China Ustekinumab Revenue Growth 2018-2023 (\$ Millions)
- Figure 58. Japan Ustekinumab Revenue Growth 2018-2023 (\$ Millions)
- Figure 59. South Korea Ustekinumab Revenue Growth 2018-2023 (\$ Millions)
- Figure 60. Southeast Asia Ustekinumab Revenue Growth 2018-2023 (\$ Millions)
- Figure 61. India Ustekinumab Revenue Growth 2018-2023 (\$ Millions)
- Figure 62. Australia Ustekinumab Revenue Growth 2018-2023 (\$ Millions)
- Figure 63. China Taiwan Ustekinumab Revenue Growth 2018-2023 (\$ Millions)
- Figure 64. Europe Ustekinumab Sales Market Share by Country in 2022
- Figure 65. Europe Ustekinumab Revenue Market Share by Country in 2022
- Figure 66. Europe Ustekinumab Sales Market Share by Type (2018-2023)
- Figure 67. Europe Ustekinumab Sales Market Share by Application (2018-2023)
- Figure 68. Germany Ustekinumab Revenue Growth 2018-2023 (\$ Millions)
- Figure 69. France Ustekinumab Revenue Growth 2018-2023 (\$ Millions)
- Figure 70. UK Ustekinumab Revenue Growth 2018-2023 (\$ Millions)
- Figure 71. Italy Ustekinumab Revenue Growth 2018-2023 (\$ Millions)
- Figure 72. Russia Ustekinumab Revenue Growth 2018-2023 (\$ Millions)
- Figure 73. Middle East & Africa Ustekinumab Sales Market Share by Country in 2022

Figure 74. Middle East & Africa Ustekinumab Revenue Market Share by Country in 2022

Figure 75. Middle East & Africa Ustekinumab Sales Market Share by Type (2018-2023)

Figure 76. Middle East & Africa Ustekinumab Sales Market Share by Application (2018-2023)

Figure 77. Egypt Ustekinumab Revenue Growth 2018-2023 (\$ Millions)

Figure 78. South Africa Ustekinumab Revenue Growth 2018-2023 (\$ Millions)

Figure 79. Israel Ustekinumab Revenue Growth 2018-2023 (\$ Millions)

Figure 80. Turkey Ustekinumab Revenue Growth 2018-2023 (\$ Millions)

Figure 81. GCC Country Ustekinumab Revenue Growth 2018-2023 (\$ Millions)

Figure 82. Manufacturing Cost Structure Analysis of Ustekinumab in 2022

Figure 83. Manufacturing Process Analysis of Ustekinumab

Figure 84. Industry Chain Structure of Ustekinumab

Figure 85. Channels of Distribution

Figure 86. Global Ustekinumab Sales Market Forecast by Region (2024-2029)

Figure 87. Global Ustekinumab Revenue Market Share Forecast by Region (2024-2029)

Figure 88. Global Ustekinumab Sales Market Share Forecast by Type (2024-2029)

Figure 89. Global Ustekinumab Revenue Market Share Forecast by Type (2024-2029)

Figure 90. Global Ustekinumab Sales Market Share Forecast by Application (2024-2029)

Figure 91. Global Ustekinumab Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Ustekinumab Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/G6EF5BA11CC3EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6EF5BA11CC3EN.html>